Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aytu BioPharmaAYTU -0.98%42 Cash Ratio is 0.45 as of Mar. 2026, which is 6% below its 10-year median of 0.48. GuruFocus rates AYTU with a GF Score™ of 42/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 970 Drug Manufacturers companies, Aytu BioPharma ranks worse than 57.84% on this metric.
Aytu BioPharma has a Cash Ratio of 0.45. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Aytu BioPharma's Cash Ratio or its related term are showing as below:
AYTU'
s Cash Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.48 Max: 3.82
Current: 0.45
During the past 13 years, Aytu BioPharma's highest Cash Ratio was 3.82. The lowest was 0.22. And the median was 0.48.
AYTU's Cash Ratio is ranked worse than 57.84% of 970
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs AYTU: 0.45
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Aytu BioPharma Cash Ratio Related Terms
Aytu BioPharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (AYTU) has a Cash Ratio of 0.45 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Aytu BioPharma and its competitors. This is near median its historical median of 0.48. Over the past decade, Aytu BioPharma's Cash Ratio has ranged from 0.22 to 3.82. According to the industry distribution chart, Aytu BioPharma ranks #561 out of 970 companies in the Drug Manufacturers industry, placing it in the top 57.8%.
Is Aytu BioPharma's Cash Ratio too high?
Aytu BioPharma's current Cash Ratio of 0.45 is near median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 3.82. The Drug Manufacturers industry median Cash Ratio is 0.59. Aytu BioPharma's value of 0.45 is 23.7% below this industry median. Based on the distribution chart, Aytu BioPharma ranks #561 out of 970 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aytu BioPharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Cash Ratio compare to TXMD and MRMD?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #561 out of 970 companies for Cash Ratio. This places Aytu BioPharma in the lower half of its industry. The industry median Cash Ratio is 0.59. Aytu BioPharma's value of 0.45 is 23.7% below this benchmark. Historically, Aytu BioPharma's own Cash Ratio has ranged from 0.22 to 3.82 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 0.59, Aytu BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.59, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aytu BioPharma's current Cash Ratio of 0.45 is 23.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current Cash Ratio is 0.45, which is near median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $2.36 — trading 171.3% above its estimated fair value. The current Cash Ratio is 0.45, which is near median its 10-year median of 0.48 and 23.7% below the Drug Manufacturers industry median of 0.59. Aytu BioPharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Cash Ratio is 0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.36 is trading 171.3% above its estimated GF Value™ of $0.87.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
Cash Ratio: 0.45 (near median its 10-year median of 0.48)
GF Value™: $0.87 vs. price of $2.36 (171.3% above fair value)
Industry Position: 23.7% below the Drug Manufacturers median (#561 of 970)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
42GF Score
Get the complete analysis for AYTU
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
